| abstract |
REFERS TO URACIL DERIVED COMPOUNDS BICYCLICALLY SUBSTITUTED FROM FORMULA (I) WHERE R1, R2 AND R3 ARE AS DEFINED HEREIN. THE PREFERRED COMPOUNDS ARE: 3- [2-CHLORO-3- (TRIFLUOROMETHYL) BENZYL] -1- (3- (CYCLOPROPYLMEthyl) -1-METHYL-2-OXO-2,3-DIHYDRO-1H-BENZYMIDAZOLE-5-IL) ETHYL -2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; 3- [2-CHLORO-3- (TRIFLUOROMETHYL) BENZYL] -1- (1-METHYL-3- (OXETAN-2-ILMETHYL) -2-OXO-2,3-DIHYDRO-1H-BENZYMIDAZOLE-5-IL) ETHYL -2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND PREPARATION PROCEDURES. SAID COMPOUNDS ARE USEFUL KINASE INHIBITORS FOR THE TREATMENT OF HEART FAILURE, PULMONARY HYPERTENSION, ASTHMA |